Johnson & Johnson : Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

Submitted by Anonymous on

Johnson & Johnson : Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer Published on 02/23/2026 at 11:20 am EST Publicnow Share JOHNSON & JOHNSON +1.21%Home/ Media Center/...

Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia

Submitted by Anonymous on

BackgroundNon-small cell lung cancer (NSCLC) with mutations in epidermal growth factor receptor exon 20 (EGFR Ex20Ins) is rare and resistant to conventional Abstract Background: Non-small cell lung cancer (NSCLC) with mutations in epidermal growth factor receptor exon 20 (EGFR Ex20Ins)...

Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any enquiries. Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer Janssen Cilag International NV...

EGFR as a biomarker in colorectal Cancer: An electrochemical biosensing approach

Submitted by Anonymous on

Highlights•Electrochemical EGFR detection achieves picomolar-to-attomolar sensitivity.•76.9% diagnostic accuracy for anti-EGFR therapeutic response prediction.•ctDNA tracking identifies emerging resistance beyond KRAS/BRAF mutations.•Multiplex biomarker integration improves tumor phenotyping and stratification.•Multi-omics integration (EGFR, ctDNA, EV, protein biomarkers) enhances accuracy.AbstractTraditional epidermal growth factor receptor (EGFR)...

Elucidating the role of the T790M mutation in BLU-945 selectivity for mutant EGFR: structural and energetic insights

Submitted by Anonymous on

Abstract Resistance mutations in the epidermal growth factor receptor (EGFR), particularly the gatekeeper T790M mutation, pose a major challenge for tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Previous experimental studies reported that the inhibitor BLU-945 selectively...

EGFR and AR expression and co-expression in Indian triple-negative breast cancer with patient outcome association

Submitted by Anonymous on

Triple negative breast cancer (TNBC) is a highly heterogeneous disease lacking established molecular targets. Its incidence is notably higher in Indian women compared to Western populations. To characterize molecular diversity within Indian TNBCs, we analyzed 93 tumor samples for the...

Radiance Biopharma Showcases First‑in‑Class c‑MET/EGFR Bispecific Nano ADC at Leading Global ADC Conference

Submitted by Anonymous on

Introduction of a Differentiated Bispecific Nano ADC Positioned to Compete in Major Global Oncology Markets BOSTON, MA, UNITED STATES, February 20, 2026 / EINPresswire.com / -- Radiance Biopharma announced today that Chief Executive Officer Robert K. Brooks, JD will present...

Subscribe to Newsfeed